Intravenous antigen administration as a therapy for autoimmune demyelinating disease

Annals of Neurology

Volumn 39, Issue 1, 1996, Pages 46-56

  Racke, Michael K ^a,d   Critchfield, Jeffrey M ^b   Quigley, Laura ^a   Cannella, Barbara ^c   Raine, Cedric S ^c   McFarland, Henry F ^a   Lenardo, Michael J ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN BASIC PROTEIN; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALITIS; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CELL CYCLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DRUG THERAPY; FEMALE; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; MICE; MICE, INBRED STRAINS; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 0030071366     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390108     Document Type: Article

References (48)

1. Zamvil SS, Steinman L. The lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990;8:579-621
2. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10: 153-187
3. Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+2-lymphocytes. J Immunol 1981;127:1420-1423
4. Mokhtarian F, McFarlin DE, Raine CS Adoptive transfer of myelin basic protein sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature 1984;309:356-358
5. Fritz R, McFarlin DE. Encephalitogenic epitopes of myelin basic protein. Chem Immunol 1989;46:101-125
6. Tuohy VK, Sobel RA, Lees MB. Myelin proteolipid protein-induced experimental allergic encephalomyelitis: variations of disease expression in different strains of mice. J Immunol 1987; 140:1868-1873
7. Shaw C-M, Fahlberg WJ, Kies MW, Alvord EC Jr. Suppression of experimental "allergic" encephalomyelitis in guinea pigs by encephalitogenic proteins extracted from homologous brain. J Exp Med 1960;111:171-180
8. Alvord EC Jr, Shaw C-M, Hruby S, Kies MW. Encephalitogen-induced inhibition of experimental allergic encephalomyelitis: prevention, suppression, and therapy. Ann NY Acad Sci 1965;122:333-345
9. Lisak RP, Falk GA, Heinze RG, et al. Dissociation of antibody production from disease suppression m the inhibition of allergic encephalomyelitis by myelin basic protein. J Immunol 1970;104:1435-1446
10. Lisak RP, Zweiman B, Dzida L, et al. In vitro response to basic protein in experimental allergic encephalomyelitis: effect of pretreatment with basic protein in incomplete adjuvant. Cell immunol 1980;52:443-450
11. Levine S, Hoenig EM, Kies MW. Allergic encephalomyelitis: passive transfer prevented by encephalitogen. Science 1968; 161:1155-1157
12. Critchfield JM, Racke MK, Zuniga-Pflucker JC, et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994;263:1139-1143
13. Miller A, Lider O, Weiner HL. Antigen driven bystander suppression following oral administration of antigens. J Exp Med 1991;174:781-798
14. Bitar CM, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. Cell Immunol 1988;112:364-370
15. Tan L-J, Kennedy MK, Dal Canto MC, Miller SD. Successful treatment of paralytic relapses in adoptive experimental auto immune encephalomyelitis via neuroantigen-specific tolerance. J Immunol 1991;147:1797-1802
16. Sharma SD, Nag B, Su X-M, et al. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Natl Acad Sci USA 1991;88:11465-11469
17. Schwartz RH. Immunological tolerance. In: Paul WE, ed. Fundamental immunology. 3rd ed. New York: Raven, 1993:677-731
18. Lenardo MJ. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 1991;353:858-861
19. Russell JH, White CL, Loh DY, Meleedy-Rey P. Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc Natl Acad Sci USA 1991;88:2151-2155
20. Racke MK, Dhib-Jalbut S, Cannella B, et al. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J Immunol 1991; 146:3012-3017
21. Ly IA, Mishell RI. Separation of mouse spleen cells by passage through columns of Sephadex G-10. J Immunol Methods 1974;5:239-247
22. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. III. Validity tests for the single Poisson model. J Immunol Methods 1984;72:29-40
23. Albert PS. A Markoff model for sequences of ordinal data from a relapsing and remitting disease. Biometrics 1994;50:51-60
24. Su X-M, Sriram S. Treatment of chronic relapsing experimental allergic encephalomyelitis with the intravenous administration of splenocytes coupled to encephalitogenic peptide 91-103 of myelin basic protein. J Neuroimmunol 1991;34:181-190
25. Kennedy MK, Tan L-J, Dal Canto MC, et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol 1990;144:909-915
26. Matis LA, Ghimcher LH, Paul WE, Schwartz RH. Magnitude of response of histocompatibility-restricted T-cell clones is a function of the product of the concentrations of antigen and la molecules. Proc Natl Acad Sci USA 1983;80:6019-6023
27. Ceredig R, Corradin G. High antigen concentration inhibits T cell proliferation but not interleukin 2 production: examination of limiting dilution microcultures and T cell clones. Eur J Immunol 1986;16:30-34
28. Suzuki G, Kawase Y, Koyasu S, et al. Antigen-induced suppression of the proliferative response of T cell clones. J Immunol 1988;140:1359-1365
29. Moskophidis D, Lechner F, Pitcher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362.758-761
30. Boehme SA, Lenardo MJ. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur J Immunol 1993;23:1552-1560
31. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-1176
32. Raine CS. Biology of disease. The analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest 1984;50:608-635
33. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991;28:254-260
34. Wekerle H, Linnington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci 1986, 9:271-277
35. 14C-labeled cells during acute, chronic, and relapsing experimental allergic encephalomyelitis. Lab Invest 1990;2:162-170
36. Skundric DS, Kim C, Tse HY, Raine CS. Homing of T cells to the central nervous system throughout the course of relapsing experimental autoimmune encephalomyelitis in Thy-1 congenic mice. J Neuroimmunol 1993;46:113-122
37. Gonsette RE, Delmottte P, Demonty L. Failure of basic protein therapy for multiple sclerosis. J Neurol 1977;216:27-31
38. Campbell B, Vogel PJ, Fisher E, Lorenz R. Myelin basic protein administration in multiple sclerosis. Arch Neurol 1973; 29:10-15
39. Schumacher GA. Critique of experimental trials of therapy in multiple sclerosis. Neurology 1974;24:1010-1014
40. Romine JS, Salk J. A study of myelin basic protein as a therapeutic probe in patients with multiple sclerosis. In: Hallpike JF, Adams CWM, Tourtellorte WW, eds. Multiple sclerosis: pathology, diagnosis, and management. Baltimore: Williams & Wilkins, 1983:621-630
41. Alvord EC Jr, Shaw C-M, Hruby S, Kies MW. Has myelin basic protein received a fair trial in the treatment of multiple sclerosis? Ann Neurol 1979;6:461-468
42. Pelfrey CM, Tranquill LR, Boehme SA, et al. Two mechanisms of antigen-specific apoptosis of myelin basic protein (MBP)-specific T lymphocytes derived from multiple sclerosis patients and normal individuals.) Immunol 1995;154:6191-6202
43. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells re sponsive to myelin basic protein in patients with multiple sclerosis. Science 1990;247:718-721
44. Meinl E, Weber F, Drexler K, et al. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis: complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 1993;92: 2633-2643
45. Racke MK, Martin R, McFarland H, Fritz RB. Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation. J Neuroimmunol 1992;37: 75-84
46. Johnson D, Hafler DA, Fallis RJ, et al. Cell-mediated immunity to myelin associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis. J Neuroimmunol 1986;13:99-108
47. Pelfrey CM, Trotter JL, Tranquill LR, McFarland HF. Identification of a novel T cell epitope of human proteolipid protein (residues 40-60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients. J Neuroimmunol 1993;46:33-42
48. Kerlero de Rosbo N, Milo R, Lees MB, et al. Reactivity to myelin antigens in multiple sclerosis: peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993;92:2602-2608